ZURICH, March 30 (Reuters) - Switzerland's Roche Holding AG said on Friday its Xeloda drug had been approved in Europe for the treatment of advanced stomach cancer. Xeloda was approved for first-line ...
were treated with infused intravenous (IV) 5FU/FA.*(1) The individual trials compared capecitabine with the previous standard IV 5-FU/FA, ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results